News

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

New York, July 21, 2023 – Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on July...

Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference

Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW YORK, March 31, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA)...